Post by CrystalsFirst

Think Bioscience and CrystalsFirst to expand partnership following discovery of novel mechanisms of action for undruggable targets. The combination of Think Bioscience's unique synthetic biology platform with CrystalsFirst’s advanced MAGNET platform has significantly accelerated the advancement from initial targets to lead candidates, while also revealing previously unknown binding mechanisms. Novel Mechanistic Insights The collaboration between Think Bioscience and CrystalsFirst has uncovered previously unknown mechanisms of action to open new avenues for multiple previously “undruggable” targets. Rapid Target-to-Lead Progression CrystalsFirst’s MAGNET platform — integrating SmartSoak®- technology and FragAI — accelerated the progression from target to lead compound, delivering co-crystal structures. This structural biology approach confirmed novel binding pockets for differentiated therapeutic programs. Partnership Expansion Buoyed by the collaboration’s success, Think Bioscience and CrystalsFirst plan to broaden the scope of their partnership. The expansion will enable additional pipeline programs for Think Bioscience and broaden their use of the MAGNET platform in discovery efforts, with the goal of advancing more first-in-class therapies to the clinic. https://lnkd.in/e3gNjKC9 https://lnkd.in/erPhbf3K